S. Karger AG

SHERPA: Unknown

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Salles
    Salles
  5. Chaganti
    Chaganti
  6. Jhanwar
    Jhanwar
  7. Kumar
    Kumar

Groups

  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Survivorship Research (8)
  6. Population Sciences Research Program (4)
  7. Executive Committee, Center for Hematologic Malignancies (1)
Search Within
  1. "Lymphoma"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Survivorship Research (8)
  6. Population Sciences Research Program (4)

More Groups

People
  1. Andrew Zelenetz (8)
  2. Matthew Matasar (8)
  3. Maria Palomba (4)
  4. Steven Horwitz (4)
  5. Andre Goy (2)
  6. Frederic Gilles (2)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (3)
  5. 2020 (3)
  6. 2019 (3)

More Years

Publications
  1. Oncology Research and Treatment (21)
  2. Acta Haematologica (2)
  3. Cytogenetic and Genome Research (1)
  4. Cytogenetics and Cell Genetics (1)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Borchmann, P.; Morschhauser, F.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jäger, U.; Cartron, G.; Izutsu, K.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Fay, K.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin + rituximab, cyclophosphamid, doxorubicin und prednison (Pola-R-CHP) im vergleich zu rituximab, cyclophosphamid, doxorubicin, vincristin und prednison (R-CHOP) bei patient: Innen mit unbehandeltem diffusemgroßzelligem B-zell-lymphom (DLBCL): Ergebnisse der phase III POLARIX studie
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab-monotherapie ist eine wirksame und gut verträgliche behandlungsoption bei patienten mit rezidiviertem/refraktärem follikulärem lymphom, die zuvor bereits ≥2 therapielinien erhalten haben: Wichtige ergebnisse einer phase-I/II-studie
    Meeting Abstract

    Hess, G.; Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
    Meeting Abstract

    Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save